Published on October 8, 2009 at 4:42 AM
Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA").
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
The Company is now awaiting GMP certification to manufacture Gabexate mesylate.
SOURCE Sinobiopharma, Inc.